Chronic idiopathic urticaria successfully treated by anticoagulant drug

European Journal of Dermatology

Volumn 22, Issue 6, 2012, Pages 788-790

  Spring, Philip ^a   Angelillo Scherrer, Anne ^a   Bigliardi, Paul ^b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; ANTICOAGULANT AGENT; CHLOROQUINE; CYCLOSPORIN A; DAPSONE; FRAXIPARAN; NADROPARIN; ROFECOXIB; UNCLASSIFIED DRUG;

ADULT; ANTIPHOSPHOLIPID SYNDROME; CASE REPORT; CHRONIC IDIOPATHIC URTICARIA; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HUMAN; LABORATORY TEST; LEUKOCYTOSIS; NOTE; PATIENT ASSESSMENT; RELAPSE; THROMBOCYTOSIS; TREATMENT DURATION; URTICARIA;

ACENOCOUMAROL; ANTICOAGULANTS; ANTITHROMBIN III; CHRONIC DISEASE; DOUBLE-BLIND METHOD; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HUMANS; MIDDLE AGED; NADROPARIN; PEPTIDE FRAGMENTS; PEPTIDE HYDROLASES; PROTHROMBIN; URTICARIA; VENOUS THROMBOSIS;

EID: 84877072225     PISSN: 11671122     EISSN: 19524013     Source Type: Journal    
DOI: 10.1684/ejd.2012.1867     Document Type: Note

References (6)

1. Asero R, Riboldi P, Tedeschi A, Cugno M, Meroni P. Chronic urticaria: a disease at a crossroad between autoimmunity and coagulation. Autoimmunity reviews 2007; 7: 71-76.
2. Asero R, Tedeschi A. Emerging drugs for chronic urticaria. Expert opinion on emerging drugs 2006; 11: 265-274.
3. Cugno M, Marzano AV, Asero R, Tedeschi A. Activation of blood coagulation in chronic urticaria: pathophysiological and clinical implications. Internal and emergency medicine 2010; 5: 97-101.
4. Cugno M, Marzano AV, Tedeschi A, Fanoni D, Venegoni L, Asero R. Expression of tissue factor by eosinophils in patients with chronic urticaria. International archives of allergy and immunology 2009; 148: 170-174.
5. Boehncke WH, Ludwig RJ, Zollner TM, Ochsendorf F, Kaufmann R, Gibbs BF. The selective cyclooxygenase-2 inhibitor rofecoxib may improve the treatment of chronic idiopathic urticaria. The British journal of dermatology 2003; 148: 604-606.
6. Maurer M, Altrichter S, Bieber T, et al. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase. The Journal of allergy and clinical immunology 2011; 128: 202-9 e5.